Tranexamic Acid Dosing and Duration for Abnormal Uterine Bleeding
For abnormal uterine bleeding (AUB), tranexamic acid should be given at 1 gram orally three to four times daily (total 3-4 grams/day) for 4-5 days starting from the first day of menstruation, and can be used cyclically for as long as needed to control bleeding.
Dosing Regimen
The standard oral dosing for AUB is:
- 1 gram (1000 mg) three to four times daily during menstruation
- Total daily dose: 3-4 grams per day
- Duration per cycle: 4-5 days (starting on day 1 of menses)
- Treatment is given only during days of active bleeding, not continuously throughout the month 1, 2, 3
Some guidelines suggest starting at 500 mg twice daily and gradually increasing up to 1000 mg four times daily or 1500 mg three times daily if needed, particularly for epistaxis in hereditary hemorrhagic telangiectasia, though this approach can be adapted for AUB 4.
Duration of Treatment
Tranexamic acid can be used cyclically for extended periods:
- Studies demonstrate efficacy for at least 3-6 treatment cycles 2, 5
- Long-term use has been documented for up to 8 years without retinal changes in safety monitoring 6
- Treatment should continue as long as clinically needed to control heavy menstrual bleeding
- There is no arbitrary time limit for cyclic use during menses 1, 5
The key distinction is that tranexamic acid is taken only during menstruation (typically 4-5 days per month), not continuously, which allows for safe long-term management.
Efficacy Expectations
Patients should expect:
- 40-60% reduction in menstrual blood loss 1, 2, 3
- Significant improvement typically seen within 2-3 treatment cycles 1
- 81% patient satisfaction in quality-of-life studies 5
- Superior efficacy compared to NSAIDs, etamsylate, or luteal-phase progestins 1, 3, 5
Important Clinical Considerations
Contraindications
- Active thromboembolic disease (absolute contraindication) 6
- History of thrombosis or intrinsic thrombophilia (FDA considers this a contraindication, though evidence of increased thrombotic risk is limited) 6, 1
- Subarachnoid hemorrhage 6
- Hypersensitivity to tranexamic acid 6
Dose Adjustments for Renal Impairment
For patients with renal dysfunction, reduce dosing as follows 6:
- Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
- Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
- Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours or 5 mg/kg every 24 hours
Safety Profile
- Most adverse effects are mild gastrointestinal symptoms (nausea, vomiting, diarrhea) occurring in approximately 12% of patients 5
- No evidence of increased thrombotic events in menorrhagia treatment despite theoretical concerns 1, 7
- Risk of seizures exists primarily with IV administration at high doses (not relevant for oral AUB treatment) 6
- Visual disturbances are rare; consider ophthalmologic monitoring only if treatment exceeds 3 months 6
Alternative Considerations
If tranexamic acid fails or is contraindicated:
- Levonorgestrel-releasing intrauterine system (LNG-IUS) is more effective (96% reduction in blood loss) and recommended as first-line therapy in some contexts, particularly for patients with bleeding disorders 8
- NSAIDs (mefenamic acid, ibuprofen) reduce blood loss by 20-30% but are less effective than tranexamic acid 3, 5
- Combination therapy with desmopressin (DDAVP) may be considered for patients with underlying bleeding disorders 8
Common Pitfalls to Avoid
- Don't delay treatment: Start on day 1 of menstruation for optimal efficacy
- Don't use continuously: Tranexamic acid is taken only during active bleeding days, not throughout the menstrual cycle
- Don't combine with hormonal contraceptives without caution: Theoretical increased thrombotic risk, though clinical evidence is limited 6
- Don't assume thrombotic risk: Despite FDA warnings, studies show no increased thrombosis in menorrhagia patients 1, 7
- Don't forget renal dosing: Adjust for creatinine clearance to prevent accumulation 6